Advancing Nanoparticle Technology Creating Opportunities For Drug Developers - Examining Technology, Therapeutic And Market Factors
Main Category: Pharma Industry / Biotech IndustryAlso Included In: Medical Devices / Diagnostics
Article Date: 04 Jun 2008 - 5:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
Advances in nanotechnology that enable drugs to be delivered in ways that preserve their efficacy and to precise therapeutic targets are creating a host of opportunities for drug developers. A variety of nanostructures are being investigated as functional drug carriers for a wide range of therapies, most notably cardiovascular medicine, autoimmune diseases, and cancer.
While the concept of nanoparticles in drug delivery is not new, the number of research programs and active drug development projects has escalated as funding to nanotechnology developers has increased. The result is the emergence of a host of novel nanotechnologies tailored to meet the physicochemical requirements of drug developers.
Nanoparticles have already improved the availability and efficacy of some drugs, but the capabilities that evolving technologies possess will leads to a dramatic increase in the number of therapies delivered via nanoparticles. In many cases drugs in nanocrystalline form can be administered in smaller doses because they can be delivered directly to the tissue and in controlled doses related to the patient's personal requirements.
These findings are contained in a new and comprehensive report: "Nanoparticle Drug Delivery: Technologies, Targets and Therapies." The survey concludes that nanoparticle-based drug delivery will gain traction at the expense of traditional drug formulation methods, particularly among emerging biologics.
More information is available at http://www.greystoneassociates.org.
About Greystone
Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment.
Greystone Associates
Visit our pharma industry / biotech industry section for the latest news on this subject.
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/109896.php>
APA
http://www.medicalnewstoday.com/releases/109896.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



